Comparison of the Whole-Body Bone Scintigraphy with Levels of the Markers of Bone Metabolism in Serum of Patients with Malignant Melanoma

1. Bayraktutan U, Kantarci M, Pirimoglu B, Ogul H, Okur A, Gursan N. Utility of diffusion-weighted imaging in the diagnosis of inguinal lymph node metastasis with malignant melanoma. World J Clin Cases 2014; 2(2): 42-4.10.12998/wjcc.v2.i2.42393621924579071Search in Google Scholar

2. Higgins HW, Lee KC, Leffell DJ. Point of care cutaneous imaging technology in melanoma screening and mole mapping. F1000Prime Rep 2014; 6: 34.10.12703/P6-34401791024860656Search in Google Scholar

3. Zbytek B, Carlson JA, Granese J, Ross J, Mihm MC, Slominski A. Current concepts of metastasis in melanoma. Expert Rev Dermatol 2008; 3(5): 569-85.10.1586/17469872.3.5.569260164119649148Search in Google Scholar

4. Jain D, Singh T, Kumar N, Daga MK. Metastatic malignant melanoma in bone marrow with occult primary site - a case report with review of literature. Diagnostic Pathology 2007; 2: 38.10.1186/1746-1596-2-38214005217910749Search in Google Scholar

5. Serrier C, Lesesve JF. Metastatic malignant melanoma in the bone marrow. Blood 2013; 121(5): 721.10.1182/blood-2012-09-45454623484212Search in Google Scholar

6. Potepan P, Spagnoli I, Danesini GM, Laffranchi A, Gadda D, Mascheroni L, Guzzon A. The radiodiagnosis of bone metastases from melanoma. Radiol Med 1994; 87(6): 741-6.Search in Google Scholar

7. Zhang Y, Zhao Ch, Liu H, Hou H, Zhang H. Multiple Metastasis-Like Bone Lesions in Scintigraphic Imaging. J Biomed Biotechnol 2012; 2012: 957364.10.1155/2012/957364331246422505821Search in Google Scholar

8. Brenner AI, Koshy J, Morey J, Lin C, DiPoce J. The bone scan. Semin Nucl Med 2012; 42(1): 11-26. 10.1053/j.semnuclmed.2011.07.00522117809Search in Google Scholar

9. Ghosh P. The role of SPECT/CT in skeletal malignances. Semin Musculoskelet Radiol 2014; 18(2): 175-93.10.1055/s-0034-137101924715449Search in Google Scholar

10. Krzhivitskii PI, Kanaev SV, Novikov SN, Zhukova LA, Ponomarëva OI, Negustorov IuF. SPECT-CT in the diagnosis of metastatic skeletal lesion. Vopr Onkol 2014; 60(1): 56-63.Search in Google Scholar

11. Kuwert T. Bone Imaging with SPECT-CT. In: Fanti S, Farsad M, Mansi L et al. Atlas of SPECT/CT. Springer - Verlag Berlin Heidelberg 2011: 105-19.10.1007/978-3-642-15726-4_4Search in Google Scholar

12. Tan JC, Chatterton BE. Is there an added clinical value of “true“ whole body (18)F-FDG PET/CT imaging in patients with malignant melanoma? Hell J Nucl Med 2012; 15(3): 202-5.Search in Google Scholar

13. Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Med 2012; 53(8): 1244-52.10.2967/jnumed.112.10930622782313Search in Google Scholar

14. Laurent V, Trausch G, Bruot O, Olivier P, Felblinger J, Régent D. Comparative study of two whole-body imaging techniques in the case of melanoma metastases: advanteges of multi-contrast MRI examination including a diffusion-weighted sequence in comparison with PET-CT. Eur J Radiol 2010; 75(3): 376-83.10.1016/j.ejrad.2009.04.059Search in Google Scholar

15. Kardamakis D, Vassilious V, Chow E. Bone metastases. A Translational and Clinical Approach. Springer Science + Business Media B.V. 2009: 400.10.1007/978-1-4020-9819-2Search in Google Scholar

16. Abdel-Sater KA, Mansour H. Bone biomarkers of ovariectomised rats after leptin therapy. Bratisl Lek Listy 2013; 114(6): 303-7.Search in Google Scholar

17. Biver E. Use of bone turnover markers in clinical practice. Curr Opin Endocrinol Diabetes Obes 2012; 19(6): 468-73.10.1097/MED.0b013e3283591492Search in Google Scholar

18. D Oronzo S, Tamma A, Simone V, Longo V, Silvestris F. Bone health in the oncologic patient. Recenti Prog Med 2012; 103(10): 373-83.Search in Google Scholar

19. Brountzos E, Panagiotou I, Bafaloukos D, Kelekis D. Bone metastases from malignant melanoma: a retrospective review and analysis of 28 cases. Radiol Oncol 2001; 35(3): 209-14.Search in Google Scholar

20. Brown JP, Delmas PD, Malaval L, Edouard G, Chapuy MC, Meunier PJ. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet1984; i:1091-4.10.1016/S0140-6736(84)92506-6Search in Google Scholar

21. Bataille R, Delmas PD, Chappard D, Sany J. Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications. Cancer 1990; 66(1): 167-72.10.1002/1097-0142(19900701)66:1<167::AID-CNCR2820660130>3.0.CO;2-9Search in Google Scholar

22. Delmas PD, Demiaux B, Malaval L, Chapuy MC, Edouard C, Meunier PJ. Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia. Comparison with bone histomorphometry. J Clin Invest 1986; 77: 985-91.10.1172/JCI112400Search in Google Scholar

23. Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE. Metabolic effects of pamidronate in patients with metastatic bone disease. Br J cancer 1996; 73: 1089-95.10.1038/bjc.1996.210Search in Google Scholar

24. Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. J Clin Oncol 1997; 15: 131-8.10.1200/JCO.1997.15.1.131Search in Google Scholar

25. Zulauf N, Marzi I, Oremek GM. Prognostic value of bone marker beta-crosslaps in patiens with breast carcinoma. J Mol Biomark Diagn 2014; 5: 193.Search in Google Scholar